港股異動 | 耐世特(1316.HK)直線拉昇漲7% 投行看高公司股價至7.4港元
格隆匯10月21日丨耐世特(1316.HK)股價直線拉昇,現報6.86港元,漲幅7.02%,最新總市值172.02億港元;該股月內累計漲幅28%。匯豐研究研報指,美國汽車業銷售勝預期,但生產目前仍未完全復甦,令庫存處於低水平,故相信未來生產會持續向上,補庫存的行動將持續至明年,料有助帶動耐世特當地收入。除此外,公司在美國的盈利水平和歐洲的市佔率亦見增加。該行升耐世特2020至2022年盈利預測分別6%、21%及18%,維持“買入”評級,目標價由5.9港元升至7.4港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.